Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Real-life performance of a COVID-19 rapid antigen detection test targeting the SARS-CoV-2 nucleoprotein for diagnosis of COVID-19 due to the Omicron variant

Paula de Michelena, Ignacio Torres, Ángela Ramos-García, Victoria Gosalbes, Nidia Ruiz, Ana Sanmartín, Pilar Botija, Sandrine Poujois, Dixie Huntley, Eliseo Albert, David Navarro
doi: https://doi.org/10.1101/2022.02.02.22270295
Paula de Michelena
1Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ignacio Torres
1Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ángela Ramos-García
2Health Care center Benimaclet, Health Department Clínico-Malvarrosa, Valencia, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Victoria Gosalbes
3Health Care center Salvador Pau, Health Department Clínico-Malvarrosa, Valencia, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nidia Ruiz
4Health Care center Serrería, Health Department Clínico-Malvarrosa, Valencia, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ana Sanmartín
5Primary Health Directorate, Health Department Clínico-Malvarrosa, Valencia, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pilar Botija
5Primary Health Directorate, Health Department Clínico-Malvarrosa, Valencia, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sandrine Poujois
1Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dixie Huntley
1Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eliseo Albert
1Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Navarro
1Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain
6Department of Microbiology, School of Medicine, University of Valencia, Valencia, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: david.navarro@uv.es
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Objectives It has been suggested that rapid antigen detection assays (RADT) may perform suboptimally in terms of sensitivity for the diagnosis of SARS-CoV-2 Omicron variant infection. To address this issue, we conducted a prospective study in primary health centers to evaluate the clinical performance of the Panbio™ COVID-19 Ag Rapid Test Device in nasopharyngeal specimens (NP) carried out at the point of care.

Methods We recruited 244 patients (median age, 40 years; range 2–96; 141 female) with clinical suspicion of COVID-19 (232 adults and 12 children). 228/244 patients had been fully vaccinated (two doses) with licensed COVID-19 vaccines prior to recruitment. Most patients (222/244) were SARS-CoV-2 naïve prior to enrollment. Patients were tested by RT-PCR and RADT within 5 days since symptoms onset.

Results 126 patients (51.6%) tested positive by both RT-PCR and RADT, 90 patients (36.8%) returned negative results by both assays and 28 patients (11.4%) yielded discordant results (RT-PCR+/RADT-). No patients tested RT-PCR-/RADT+. Overall specificity and sensitivity of RADT was 100% (95% CI, 95.9–100%) and 81.8% (95% CI, 75–87.1%) respectively. The sensitivity of the assay increased from 79.6% (95% CI, 66.4–88.5) when considering specimens collected at days 0–1 after symptoms onset, to 86.4% (95% CI, 66.7–95.3) when grouping the specimens obtained on days 4–5.

Conclusion The Panbio™ COVID-19 Ag Rapid Test Device perform well (≥80% sensitivity) as a point-of-care test for early diagnosis of COVID-19 due to the Omicron variant in primary healthcare centers.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This research received no public or private financial support.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study was approved by the Hospital Clinico de Valencia (HCU) INCLIVA Research Ethics Committee. Since the testing strategy was considered as regular clinical practice according to local health authorities, written informed consent was waived by this committee.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The data that support the findings of this study are available on request from the corresponding author

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted February 02, 2022.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Real-life performance of a COVID-19 rapid antigen detection test targeting the SARS-CoV-2 nucleoprotein for diagnosis of COVID-19 due to the Omicron variant
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Real-life performance of a COVID-19 rapid antigen detection test targeting the SARS-CoV-2 nucleoprotein for diagnosis of COVID-19 due to the Omicron variant
Paula de Michelena, Ignacio Torres, Ángela Ramos-García, Victoria Gosalbes, Nidia Ruiz, Ana Sanmartín, Pilar Botija, Sandrine Poujois, Dixie Huntley, Eliseo Albert, David Navarro
medRxiv 2022.02.02.22270295; doi: https://doi.org/10.1101/2022.02.02.22270295
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Real-life performance of a COVID-19 rapid antigen detection test targeting the SARS-CoV-2 nucleoprotein for diagnosis of COVID-19 due to the Omicron variant
Paula de Michelena, Ignacio Torres, Ángela Ramos-García, Victoria Gosalbes, Nidia Ruiz, Ana Sanmartín, Pilar Botija, Sandrine Poujois, Dixie Huntley, Eliseo Albert, David Navarro
medRxiv 2022.02.02.22270295; doi: https://doi.org/10.1101/2022.02.02.22270295

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (227)
  • Allergy and Immunology (504)
  • Anesthesia (110)
  • Cardiovascular Medicine (1238)
  • Dentistry and Oral Medicine (206)
  • Dermatology (147)
  • Emergency Medicine (282)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (531)
  • Epidemiology (10020)
  • Forensic Medicine (5)
  • Gastroenterology (499)
  • Genetic and Genomic Medicine (2452)
  • Geriatric Medicine (236)
  • Health Economics (479)
  • Health Informatics (1642)
  • Health Policy (752)
  • Health Systems and Quality Improvement (636)
  • Hematology (248)
  • HIV/AIDS (533)
  • Infectious Diseases (except HIV/AIDS) (11864)
  • Intensive Care and Critical Care Medicine (626)
  • Medical Education (252)
  • Medical Ethics (74)
  • Nephrology (268)
  • Neurology (2280)
  • Nursing (139)
  • Nutrition (352)
  • Obstetrics and Gynecology (454)
  • Occupational and Environmental Health (536)
  • Oncology (1245)
  • Ophthalmology (377)
  • Orthopedics (134)
  • Otolaryngology (226)
  • Pain Medicine (157)
  • Palliative Medicine (50)
  • Pathology (324)
  • Pediatrics (730)
  • Pharmacology and Therapeutics (312)
  • Primary Care Research (282)
  • Psychiatry and Clinical Psychology (2280)
  • Public and Global Health (4832)
  • Radiology and Imaging (837)
  • Rehabilitation Medicine and Physical Therapy (491)
  • Respiratory Medicine (651)
  • Rheumatology (285)
  • Sexual and Reproductive Health (238)
  • Sports Medicine (227)
  • Surgery (267)
  • Toxicology (44)
  • Transplantation (125)
  • Urology (99)